Intelligent Investor

CSL Limited

By · 7 Feb 2003
By ·
7 Feb 2003
Upsell Banner

Recommendation

CSL Limited - CSL
Current price
$269.49 at 16:35 (19 April 2024)

Price at review
$15.36 at (07 February 2003)
All Prices are in AUD ($)
Shares in this blood fractionation company continue to provide a rollercoaster ride for shareholders, falling 28% since we last reviewed the company. Recent jitters emerged after US biotech company HemCon received approval from the FDA to start marketing a trauma bandage. CSL has been developing a similar bandage that will stop bleeding even when applied to large wounds. However, CSL's bandage is 2-3 years away from being commercially available and so HemCon will have several years of uninterrupted sales. This latest news comes on top of the recent decision by rivals Aventis and Bayer to cease plans on merging their blood products units. The merger was expected to reduce the price volatility in the competitive IVIG market in which CSL sells its products. HOLD FOR THE UPSIDE.
IMPORTANT: Intelligent Investor is published by InvestSMART Financial Services Pty Limited AFSL 226435 (Licensee). Information is general financial product advice. You should consider your own personal objectives, financial situation and needs before making any investment decision and review the Product Disclosure Statement. InvestSMART Funds Management Limited (RE) is the responsible entity of various managed investment schemes and is a related party of the Licensee. The RE may own, buy or sell the shares suggested in this article simultaneous with, or following the release of this article. Any such transaction could affect the price of the share. All indications of performance returns are historical and cannot be relied upon as an indicator for future performance.
Share this article and show your support

Join the Conversation...

There are comments posted so far.

If you'd like to join this conversation, please login or sign up here